WO1999067288A1 - Peptides d'antigenes tumoraux provenant de la cyclophiline b - Google Patents
Peptides d'antigenes tumoraux provenant de la cyclophiline b Download PDFInfo
- Publication number
- WO1999067288A1 WO1999067288A1 PCT/JP1999/003360 JP9903360W WO9967288A1 WO 1999067288 A1 WO1999067288 A1 WO 1999067288A1 JP 9903360 W JP9903360 W JP 9903360W WO 9967288 A1 WO9967288 A1 WO 9967288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor antigen
- hla
- peptide
- amino acid
- tumor
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 343
- 108091007433 antigens Proteins 0.000 title claims abstract description 337
- 102000036639 antigens Human genes 0.000 title claims abstract description 337
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 334
- 239000000427 antigen Substances 0.000 title claims abstract description 292
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 87
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 title claims abstract description 69
- 108010048032 cyclophilin B Proteins 0.000 title claims abstract description 69
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 title claims abstract description 69
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 108010068682 Cyclophilins Proteins 0.000 claims abstract description 37
- 102000001493 Cyclophilins Human genes 0.000 claims abstract description 37
- 239000004480 active ingredient Substances 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 85
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 77
- 150000001413 amino acids Chemical group 0.000 claims description 59
- 230000027455 binding Effects 0.000 claims description 38
- 125000000539 amino acid group Chemical group 0.000 claims description 35
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 30
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 23
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 20
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 229930182817 methionine Natural products 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 15
- 230000000069 prophylactic effect Effects 0.000 claims description 14
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 229960000310 isoleucine Drugs 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 239000000032 diagnostic agent Substances 0.000 claims description 8
- 229940039227 diagnostic agent Drugs 0.000 claims description 8
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 101000951598 Caenorhabditis elegans Peptidyl-prolyl cis-trans isomerase 8 Proteins 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 9
- -1 derivatives thereof Proteins 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 239000012634 fragment Substances 0.000 abstract description 2
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 60
- 229940024606 amino acid Drugs 0.000 description 51
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 32
- 239000013612 plasmid Substances 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000002299 complementary DNA Substances 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 210000004698 lymphocyte Anatomy 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 102100037850 Interferon gamma Human genes 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 14
- 238000011282 treatment Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000013613 expression plasmid Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229950003063 mitumomab Drugs 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 7
- 108010072210 Cyclophilin C Proteins 0.000 description 7
- 108010048028 Cyclophilin D Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 229920001917 Ficoll Polymers 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002998 immunogenetic effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 3
- 241000132539 Cosmos Species 0.000 description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 description 3
- 108010072220 Cyclophilin A Proteins 0.000 description 3
- 102000011786 HLA-A Antigens Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000010039 intracellular degradation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical group N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
- 108010080347 HLA-A*26 antigen Proteins 0.000 description 2
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- HSSCMXLPZYMLKT-UHFFFAOYSA-N ethane-1,1-dithiol;2,2,2-trifluoroacetic acid Chemical compound CC(S)S.OC(=O)C(F)(F)F HSSCMXLPZYMLKT-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a novel heavy tumor antigen peptide derived from cyclophilin and the like. More specifically, cyclophilin B-derived scleroderma antigen peptide and its derivative having functionally equivalent properties, and further, these tumor antigen peptides and their derivatives, and cyclophilin B polypeptide or its gene, It relates to a therapeutic, prophylactic or diagnostic agent for tumors used in vivo or in vitro.
- TCR T cell receptor
- MHC class I antigen major histocompatibility complex class I antigen
- Tumor antigen peptides are produced by synthesizing a tumor-specific protein, ie, a tumor antigen protein, in a cell and then decomposing the protein by a proteasome in the cell.
- the generated tumor antigen peptide binds to MHC class I antigen (HLA antigen) in the endoplasmic reticulum to form a complex, which is transported to the cell surface and presented as an antigen.
- HLA antigen MHC class I antigen
- This antigen-presented complex is recognized by tumor-specific CTL, and exhibits an antitumor effect via production of cytotoxic ⁇ lymphokine.
- tumor antigen proteins or tumor antigen peptides as so-called cancer vaccines has made possible a therapeutic method that enhances fl ulcer-specific CTL in the body of fl sever patients.
- MAGE As a tumor antigen protein, T. Boon et al. First identified a protein named MAGE in human melanoma cells in 1991 (Science, 254: 1643, 1991). Since then, several tumor antigen proteins have been identified, mainly from melanoma cells.
- Melanomas antigens include gplOO (J. Exp. Med., 179: 1005, 1994), a melanocyte tissue-specific protein, and MART-1 (Proc. Natl. Acad. Sci. USA, 91: 3515,
- flA markers such as PSA (J. Natl. Cancer.Inst., 87: 982, 1995), flA markers such as PSA (J. Natl. Cancer.Inst., 89: 293, 1997), HPV (J. Immunol., 154: 5934, 1995), EBV
- tumors that can be widely applied to epithelial J tumors such as gastric and lung cancers, which are overwhelmingly more frequent than melanomas Identification of the antigen is important.
- the present inventors cloned a gene encoding a novel tumor antigen protein from squamous cell carcinoma cells derived from esophageal cancer, and bound to an HLA antigen whose HLA type is HLA-A24 or HLA-A26.
- HLA-A24 or HLA-A26 HLA-A24 or HLA-A26.
- several tumor antigen peptides proposed by the present inventors have been identified from tumor cells other than melanoma (J. Exp. Med., 187: 277, 1998, International Publication W097 / 46676).
- tumor antigen peptides When these tumor antigen peptides are actually applied to clinical practice, it is desirable to use not only one kind but also a plurality of different tumor antigen peptides. That is, all cancers Not all cells express the same tumor antigen in common, and considering that two or more different tumor antigen peptides are presented on one cancer cell, multiple different tumor antigens are expressed. Treatment with peptides appears to be more effective. In fact, in melanoma, a single tumor antigen-derived peptide alone was not sufficiently effective, and attempts have been made to develop cocktail formulations of multiple peptides.
- An object of the present invention is to provide a novel tumor antigen peptide derived from cyclophilin and the like. More specifically, cyclophilin B-derived heavy tumor antigen peptide and its derivatives having functionally equivalent properties, and further, these tumor antigen peptides and their derivatives, and cyclophilin B polypeptide or its gene It is intended to provide a therapeutic, prophylactic or diagnostic agent for tumors utilizing in vivo or in vitro.
- the cyclophilin B-derived tumor antigen peptide of the present invention includes HLA antigens possessed by Japanese and Caucasians with high probability, that is, tumor antigen peptides that are presented by binding to HLA-A24 and HLA-A2.
- those with epithelial tumors such as lung cancer, bladder cancer, and osteosarcoma, and those for the treatment of widespread tumors such as leukemia, are tumor antigen peptides that can be applied for prevention. Therefore, the cyclophilin B which is the fl sever antigen protein of the present invention and its gene, or the tumor antigen peptide derived from the cyclophilin B is expected to be useful as a novel antitumor agent.
- the present inventors made the following attempts to obtain a new tumor antigen peptide and a tumor antigen protein from which it is derived.
- the present inventors established a CTL line that recognizes HLA-A2-positive bladder cancer, lung cancer, osteosarcoma or leukemia cell lines, etc., from lymphocytes of lung adenocarcinoma patients. It was named KG-CTL (Accession number: FERM BP-6725).
- a cDNA library was obtained from the bladder cancer cell line HT-1376 to which KG-CTL strongly reacted.
- a Li one, recombinant plasmid of the library one HLA- A 24 02 (HLA- A2 4 of a kind) cDNA of a recombinant plasmid by double transfected Hue transfected into COS- 7 cells, the bets Ransufu
- the screening in which the KG-CTL is allowed to act on the actant and whether or not the KG-CTL is activated is measured by the amount of IFN-y production, one tumor antigen is finally obtained.
- Successfully cloned protein genes As a result of nucleotide sequence determination, it was revealed that the tumor antigen protein had the same amino acid sequence as a known protein called cyclophilin B.
- Cyclophilin B is a binding protein of cyclosporin A, an immunosuppressant, and is known to be involved in activation of immune cells. However, its function as a tumor antigen was not known at all before the present invention.
- the present inventors next identified, in the amino acid sequence of the cyclophilin B, a tumor antigen peptide portion which is presented by binding to HLA-A24 and HLA-A2, and these peptides and the peptide were identified. It has been clarified that some derivatives have activity as tumor antigen peptides.
- cyclophilin B a homolog of cyclophilin B.
- Cyclophilin C and Cyclophilin D were also found to have activity as tumor antigen proteins, as did Cyclophilin B.
- the present invention has been completed based on the above findings.
- tumor antigen peptide that is a partial peptide derived from cyclophilin B and that can be recognized by cytotoxic T cells by binding to an HLA antigen, or a derivative thereof having functionally equivalent properties;
- SEQ ID NO: 1 to SEQ ID NO: 36, or SEQ ID NO: 41 to SEQ ID NO: 4 The tumor antigen peptide according to (3), or a derivative thereof having functionally equivalent properties, selected from a sequence containing all or a part of the amino acid sequence according to any of (3).
- the tumor antigen peptide according to (4) which is selected from a sequence containing all or a part of the amino acid sequence described in SEQ ID NO: 1 or SEQ ID NO: 2, or has functionally equivalent characteristics Its derivatives,
- SEQ ID NO: 1 to SEQ ID NO: 11 the second position of the amino acid sequence described in any of the above is replaced with tyrosine, phenalanine, methionine or tryptophan, and the Z or C-terminal amino acid residue
- the tumor antigen peptide derivative according to (8) which is selected from a sequence containing all or a part of the amino acid sequence described in SEQ ID NO: 37 or SEQ ID NO: 38;
- the tumor antigen peptide derivative according to (10) which is selected from a sequence containing all or a part of the amino acid sequence described in SEQ ID NO: 39 or SEQ ID NO: 40.
- a therapeutic or prophylactic agent for a tumor comprising as an active ingredient at least one selected from the tumor antigen peptides and derivatives thereof described in any one of (1) to (11) above;
- Cyclophilin or a partial polypeptide of cyclophilin containing a B swelling antigen peptide portion that can be recognized and recognized by cytotoxic T cells by binding to HLA antigen, or cyclophilin or a portion thereof A therapeutic or prophylactic agent for a tumor, comprising a gene encoding a polypeptide as an active ingredient;
- Partial polypeptide of cyclophilin B containing a tumor antigen peptide portion that can be recognized by cytotoxic T cells by binding to cyclophilin 8 or HLA antigen, or cyclophilin B or a partial polypeptide thereof A complex between the HLA antigen and the cyclophilin B-derived tumor antigen peptide, which is produced by incorporating a gene encoding Presented antigen presenting cells,
- a therapeutic agent for fl swelling comprising
- cytotoxic T cell that specifically recognizes a complex of the HLA antigen and the tumor antigen peptide or a derivative thereof according to any one of (1) to (11) above;
- a therapeutic agent for a tumor comprising the cytotoxic T cell according to (20) or (21) as an active ingredient,
- a diagnostic agent for a tumor comprising the tumor antigen peptide or the derivative thereof according to any one of the above (1) to (11) as an active ingredient.
- the present invention is based on, for the first time, the finding that a substance called cyclophilin has an activity as a tumor antigen protein.
- cyclophilin B as an embodiment of the present invention, but the following description is based on other known cyclophilins, namely, cyclophilin 8, cyclophilin C and cyclophilin D (Biochemistry, 3, p8218, 1994) and is not limited to cyclophilin B.
- the J® tumor antigen peptide is a tumor antigen peptide that is a partial peptide composed of a part of cyclophilin B and that can be recognized by CTL by binding to HLA antigen. That is, a part of the amino acid sequence of human cyclophilin B registered as Genbank Accession No. 60857 in the WWW Entrez database search and described in Pro Natl. Acad. Sci. USA, 88: pl903-1907, 1991.
- a peptide comprising a binding complex between the peptide and the HLA antigen that can be recognized by CTL, any length at any position in the amino acid sequence of the cyclophilin B. All the peptides are included in the category of the tumor antigen peptide of the present invention.
- Such a tumor anti-tumor of the present invention The original peptide synthesizes a candidate peptide consisting of a part of cyclophilin B, and determines whether or not the complex of the candidate peptide and the HLA antigen is recognized by CTL, that is, the candidate peptide is used as a tumor antigen peptide. It can be identified by assessing whether or not it has the activity.
- the peptide can be synthesized according to a method used in ordinary peptide chemistry.
- Examples of the known method include literatures (Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol 2, Academic Press Inc., New York, 1976; Peptide Synthesis, Maruzen, 1975; Fundamentals and experiments of peptide synthesis; Maruzen, 1985; Development of pharmaceuticals continued Vol. 14: Peptide synthesis, Hirokawa Shoten, 1991).
- sequence regularity (motif) of the antigenic peptide presented by binding to the HLA has been known (see, for example, 1 Maraudal ⁇ 3 ⁇ 46063, 41178, 1995, etc.). thing) .
- the second amino acid of the peptide consisting of 8 to 11 amino acids is tyrosine, fenylalanine, methionine or tryptophan, and the C-terminal amino acid is fenylalanine, leucine, Known to be isoleucine, tryptophan or methionine
- the length of the peptide is 8 to 11 amino acids.
- the length of the peptide is usually 8 based on the analysis of antigen peptides bound to various HLA molecules (I ⁇ unogenetics, 41: 178, 1995). From 14 amino acids (except for HLA-DR, -DP, and -DQ, which have an antigen peptide length of 14 amino acids or more).
- peptide moieties related to these motifs from the amino acid sequence of cyclophilin B. That is, by looking at the amino acid sequence of the cyclophilin B, the peptide portion related to the motif structure can be easily selected.
- the selected candidate peptide is synthesized by the method described above, and whether or not the binding complex between the candidate peptide and the HLA antigen is recognized by CTL, that is, the activity of the candidate peptide as a tumor antigen peptide By measuring whether or not the tumor antigen is present, the tumor antigen peptide of the present invention can be identified.
- an expression plasmid that expresses the cDNA of the HLA antigen that is considered to present candidate peptides is introduced into, for example, COS-7 cells (ATCC No. CRL1651) or VA-13 cells (RIKEN Cell Bank).
- the cells are pulsed with a candidate peptide, the cells are reacted with the CTL, and the amount of various cytokins (for example, IFN ⁇ ) produced by the CTLs is also examined.
- Cyclophilin B has a tumor antigen peptide portion restricted to HLA-A24 and HLA-A2.
- the cDNA encoding the HLA antigen may be HLA-A24 cDNA (Cancer Res., 55: 4248-4252 (1995), Genbank Accession No. M64740), and the CTL is prepared by stimulating human peripheral blood lymphocytes with a peptide, or by using a CTL such as KG-CTL (FERM BP-6725). Can be identified.
- the tumor antigen peptide was identified by the same method as described above except that HLA-A2 cDNA (Genbank Accession No.M84379) was used. can do.
- the tumor antigen peptide of the present invention can be identified, for example, according to the method described in 097/46676.
- the sequence of the tumor antigen peptide presented by binding to HLA-A24 has a regularity (motif). Specifically, the second position of the peptide consisting of 8 to 11 amino acids Amino acids are tyrosine, fenirarayun, methionine or tryptophan, and C-terminal amino acids are feniralanine, leucine, isoleucine, It is known to be tryptophan or methionine (J. Immunol., 152, P3913, 1994, Immunogenetics, 41: pl78, 1995, J. Immunol., 155: p4307, 1994). In addition, the sequence of the tumor antigen peptide presented by binding to HLA-A2 has a similar regularity (motif), and specifically, the motifs shown in Table 1 above are known.
- HLA-A24 and HLA-A2-restricted tumor antigen peptides are partial peptides related to the above motif structure on the amino acid sequence of cyclophilin B. Examples thereof include tumor antigen peptides that can be recognized by CTL by binding to each HLA antigen.
- the HLA-A24-restricted tumor antigen peptide specifically, for example, a peptide containing all or a part of the amino acid sequence described in any one of SEQ ID NO: 1 to SEQ ID NO: 11
- examples thereof include tumor antigen peptides that can be recognized by CTLs by binding to the HLA-A24 antigen.
- examples of the HLA-A2-restricted tumor antigen peptide include a peptide containing all or a part of the amino acid sequence described in any one of SEQ ID NOS: 12 to 36.
- Examples are tumor antigen peptides that can be recognized by CTL in combination with HLA-A2 antigen.
- tumor antigen peptides that can bind to each HLA antigen and be recognized by CTL.
- the length of the peptide in 2) is, for example, about 8 to 11 amino acids from the viewpoint of binding and presentation to each HLA antigen.
- Preferred examples of the HLA-A24-restricted tumor antigen peptide of the present invention include all or part of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and bind to the HLA-A24 antigen.
- Tumor antigen peptides that can be recognized by CTL It is. That is,
- the length of the peptide of the above 2) may be about 8 to 11 amino acids from the viewpoint of being presented by binding to the HLA-A24 antigen.
- tumor antigen peptide derivative refers to one or more amino acid sequences of the tumor antigen peptide of the present invention. More preferably, it refers to a variant in which one or several amino acid residues have been modified, and which has the properties as a tumor antigen peptide that can bind to HLA antigen and be recognized by CTL.
- a tumor in which one or more amino acid residues are modified in the amino acid sequence of the tumor antigen peptide of the present invention, and which can be recognized by CTL by binding to the HLA antigen All those having an activity as an antigen peptide are included in the category of the tumor antigen peptide derivative of the present invention.
- modification means substitution, deletion, and Z or addition of an amino acid residue (including addition of an amino acid to the N-terminal or C-terminal of a peptide), and is preferable. Or substitution of an amino acid residue.
- the number and position of the amino acid residue to be substituted are arbitrary as long as the activity as a tumor antigen peptide is maintained. Since the length of the sever antigen peptide is about 8 to 14 amino acids, it is preferably in the range of one to several.
- the length of the tumor antigen peptide derivative of the present invention is preferably about 8 to 14 amino acids as in the case of the tumor antigen peptide (however, HLA-DR, -DP and -DQ have a length of 14 amino acids or more). Sometimes it is.)
- the tumor antigen peptide derivative of the present invention as described above is the tumor antigen peptide of the present invention.
- Severe ulcer can be identified by subjecting the antigen peptide to the Atsey method.
- HLA types such as -Cw0401, -Cw0602, etc.
- the sequence regularity (motif) of the antigen peptide presented by binding to the HLA has been found. Therefore, it is possible to produce a tumor antigen peptide derivative obtained by modifying the amino acid of the tumor antigen peptide of the present invention based on the motif.
- the second amino acid of the peptide consisting of 8 to 11 amino acids is tyrosine, fenylalanine, methionine or It is a tryptophan, and the amino acid at the C-terminus is known to be phenylalanine, leucine, isoleucine, tryptophan or methyoyun (J. Immunol., 152, p3913, 1994,
- a peptide comprising all or a part of an amino acid sequence in which an amino acid residue to be substituted among amino acid residues known on the motif is selected, and a tumor having the activity Antigen peptide derivatives.
- the length of “all or part” is preferably about 8 to 14 amino acids (however, HLA_DR, -DP, and -DQ may be 14 amino acids or more).
- a derivative of a tumor antigen peptide restricted to HLA-A24 or HLA-A2 for example, for a peptide having a binding motif of HLA-A24 or HLA-A2 on the amino acid sequence of cyclophilin B, The position on the motif where amino acid substitution is possible That is, a tumor antigen peptide derivative that contains all or part of the amino acid sequence in which the amino acid residue at the second or Z-terminal or the C-terminus is replaced with another amino acid residue and has the above-mentioned activity is mentioned.
- the tumor antigen peptide comprises the whole or a part of the amino acid sequence in which the amino acid residue at the 2nd position and the Z or C terminal is substituted with an amino acid residue known on the motif, and has the above activity Derivatives.
- the length of "all or a part" is preferably about 8 to 11 amino acids.
- an amino acid in which the amino acid residue at position 2 and the Z- or C-terminal of the amino acid sequence described in any of SEQ ID NOs: 1 to 36 is substituted with another amino acid residue examples include tumor antigen peptide derivatives that contain all or part of the sequence and have the above-mentioned activity.
- the amino acid residue at position 2 and the Z- or C-terminal of the amino acid sequence described in any one of SEQ ID NOs: 1 to 36 is substituted with an amino acid residue known on the motif.
- the amino acid residue at the second position of the amino acid sequence described in any one of SEQ ID NO: 1 to SEQ ID NO: 11 is replaced with tyrosine, pheny / realanine.
- the amino acid residue at the second position of the amino acid sequence described in any of SEQ ID NO: 12 to SEQ ID NO: 36 may be replaced with leucine, methionine, or phosphine.
- a tumor antigen peptide derivative having all or part of the amino acid sequence obtained by substituting isoleucine or glutamine, and substituting the amino acid residue at the V "or C-terminus with valine or leucine, and having the above activity Is exemplified.
- Preferred examples of the HLA-A24-restricted tumor antigen peptide derivative of the present invention include an amino acid residue at the second position and / or C-terminal of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2. And all or part of the amino acid sequence in which is substituted with another amino acid residue, and a tumor antigen peptide derivative having the above activity.
- a tumor antigen peptide derivative having amino acid substitution based on the motif that is, containing all or a part of the amino acid sequence of SEQ ID NO: 37 or SEQ ID NO: 38, and having the activity Is mentioned.
- Preferred examples of such tumor antigen peptide derivatives are shown in SEQ ID NO: 39 to SEQ ID NO: 40.
- cyclophilin, cyclophilin C and cyclophilin D which are homologues of cyclophilin B, are also tumor antigen proteins that generate tumor antigen peptides.
- fl swelling antigen peptides include HLA-A24 restriction such as SEQ ID NO: 41 (cyclophilin A), SEQ ID NO: 42 (cyclophilin C) and SEQ ID NO: 43 (cyclophilin D).
- Sex tumor antigen peptides Sex tumor antigen peptides.
- the tumor antigen peptide or its derivative of the present invention can be used as a therapeutic or prophylactic agent for tumors as follows.
- the tumor antigen peptides or derivatives thereof of the present invention when used for the treatment or prevention of tumor, at least one or two or more of the tumor antigen peptides or derivatives thereof of the present invention are combined, and if necessary, combined with other tumor antigen peptides and the like.
- a therapeutic or prophylactic agent for a tumor comprising the tumor antigen or its derivative of the present invention as an active ingredient is administered to a cyclophilin B-positive patient
- the tumor antigen peptide or its derivative is highly expressed in the HLA antigen of antigen presenting cells. Density-presented and presented HLA-antigen complex-specific CTL can proliferate and destroy tumor cells, thus treating a patient's tumor or preventing tumor growth and metastasis.
- the therapeutic or prophylactic agent for tumors comprising the tumor antigen peptide or its derivative of the present invention as an active ingredient can also enhance the therapeutic effect when used in combination with conventional chemotherapy or radiation therapy.
- the therapeutic or prophylactic agent for tumor comprising the tumor antigen peptide or its derivative of the present invention as an active ingredient is administered together with an adjuvant so as to effectively establish cellular immunity, or is administered in a particulate dosage form. can do.
- an adjuvant those described in the literature (Clin. Microbiol. Rev., 7: 277-289, 1994) can be applied.
- liposomal preparations, particulate preparations bonded to beads having a diameter of several / m 2, and preparations bonded to lipids are also conceivable.
- the administration method is intradermal, subcutaneous Administration, intravenous injection, etc. are considered.
- the dosage of the tumor antigen peptide of the present invention or a derivative thereof in the preparation may be appropriately adjusted depending on the disease to be treated, the age and weight of the patient, etc. Normally 0.001 mg to 1000 mg, preferably 0.001 mg 10001000 mg, more preferably O.lmg ⁇ 10 mg, which is preferably administered once every few days to several months.
- cyclophilin B protein derived from the tumor antigen peptide of the present invention or the gene encoding the cyclophilin B can also be used as a therapeutic or prophylactic agent for fl swelling.
- cyclophilin B and its gene are not only full-length but also a part thereof, even if the said part is linked, and further, the base sequence or amino acid sequence thereof is modified. Even so, as long as it contains at least one peptide moiety that can be recognized by CTL by binding to the HLA antigen, the target treatment or prevention of the tumor can be achieved.
- the “containing at least one peptide portion that can be recognized and recognized by CTL by binding to the HLA antigen” is referred to as “partial polypeptide” in the present invention.
- cyclophilin B protein or its partial polypeptide When applying cyclophilin B protein or its partial polypeptide as a therapeutic or prophylactic agent for severe ulcers, administer it in the same dosage form, administration method and dosage as the tumor antigen peptide or its derivative. Can be.
- cyclophilin B protein or its partial polypeptide When cyclophilin B protein or its partial polypeptide is administered to tumor patients, it is taken up by antigen presenting cells, and the tumor antigen peptide generated by intracellular degradation binds to HLA antigen to form a complex. Then, the complex is presented at a high density on the surface of the antigen-presenting cell, and CTLs specific to the complex efficiently grow in the body and destroy tumor cells. As described above, the treatment or prevention of a tumor is achieved.
- the following method can be used. That is, the method of administering the gene of the present invention and introducing it into cells includes a method using a viral vector and other methods (Nikkei Science, April 1994, pp. 20-45, Monthly Pharmaceutical Affairs, 36 (1), 23). -48 (1994), Experimental Medicine Special Edition, 12 (15), (1994), and references cited therein) can be applied.
- a retrovirus for example, a retrovirus, an adenovirus, an adeno-associated virus, a herpes virus, a vaccinia virus, a box virus, a polio virus, a simbis virus, or the like, may be used as the DNA virus or the RNA virus of the present invention.
- a method of incorporating and introducing DNA There is a method of incorporating and introducing DNA.
- a method using a retrovirus, an adenovirus, an adeno-associated virus, a vaccinia virus and the like is particularly preferable.
- Other methods include the method of administering the expression plasmid directly into muscle (DNA vaccine method), the ribosome method, the lipofectin method, the microinjection method, the calcium phosphate method, the electoral poration method, and the like.
- the tin method and the ribosome method are preferred.
- the in vivo method When administered by the in vivo method, it can be administered by an appropriate administration route depending on the disease, symptom and the like for the purpose of treatment. For example, it can be administered intravenously, intraarterially, subcutaneously, intradermally, intramuscularly, and the like.
- it When administered by the in vivo method, for example, it may be in the form of a liquid preparation or the like, but is generally referred to as an injection containing the DNA of the present invention, which is an active ingredient.
- a carrier may be added.
- the ribosome or membrane fusion ribosome (Sendai virus (HVJ) —liposome etc.) containing the gene of the present invention is in the form of a ribosome preparation such as a suspending agent, a freezing agent, and a centrifugal concentrated freeze agent. be able to.
- the content of the gene of the present invention in the preparation can be appropriately adjusted depending on the disease to be treated, the age and weight of the patient, etc., and is usually 0.0001 mg to 100 mg , preferably 0.001 mg to 10 mg.
- the gene of the present invention is administered once every few days to several months.
- a tumor antigen protein is highly expressed in antigen-presenting cells. Thereafter, the tumor antigen peptide generated by the intracellular degradation binds to the HLA antigen to form a complex, and the complex forms on the surface of the antigen-presenting cell. Presented at high density, this complex-specific CTL grows efficiently in the body and destroys B-heavy cells. As described above, treatment of a tumor or prevention of tumor growth and metastasis is achieved.
- cyclophilin B and its partial polypeptides that can be used as therapeutic agents, and genes encoding these substances can be produced as follows. That is, a gene encoding cyclophilin B was prepared by preparing an appropriate PCR primer based on the nucleotide sequence of the cDNA of human cyclophilin B registered as Genbank Accession No.M60857 in the WWW Entrez database search, For example, it can be easily cloned by performing a PCR reaction according to a basic book such as the Molecular Cloning 2nd Edt. Cold Spring Harbor Laboratory Press (1989). At that time, Proc. Natl. Acad.
- cyclophilin B cDNA clones ATCC No. 107758, Designations: HTNAQ 1 ⁇
- the modification can be easily performed by referring to the basic book such as Molecular Cloning.
- a method for expressing cyclophilin B protein using the gene encoding human cyclophilin B thus cleaved is, for example, carried out based on many books and documents such as the aforementioned Molecular Cloning. can do.
- a regulatory gene such as a promoter sequence that controls transcription (eg, trp, lac, T7, SV40 initial promoter) is added upstream of the expressed DNA, and an appropriate vector (eg, p SV—SPORT 1) to create an expression plasmid that replicates and functions in host cells.
- an appropriate vector eg, p SV—SPORT 1
- the expression plasmid is introduced into a suitable host cell to obtain a transformant.
- the host cell include prokaryotes such as E. coli, unicellular eukaryotes such as yeast, and multicellular eukaryote cells such as insects and animals.
- Methods for introducing genes into host cells include the calcium phosphate method, the DEAE-dextran method, and the electric pulse method.
- the transformant produces the target protein by culturing in a suitable medium.
- the tumor antigen protein obtained as described above can be isolated and purified by a general biochemical method. Whether or not the cyclophilin B protein and its partial polypeptides produced as described above and the gene encoding these substances have the activity as a tumor antigen, that is, the intracellular degradation of the protein Thus, whether a tumor antigen peptide that can be recognized by CTL by binding to an HLA antigen is generated can be measured by a method using gene expression as described below, for example.
- candidate genes or genes for cells that do not express tumor antigen proteins such as African green monkey kidney-derived COS-7 (ATCC CRL1651) and ⁇ i blast cells VA-13 (RIKEN Cell Development Bank) Double-transfect the expression plasmid with the fragment and the expression plasmid with the DNA encoding the HLA antigen.
- the transfecting can be performed, for example, by a lipofectin method using a ribofectamine reagent (GIBCO BRL).
- a tumor-reactive CTL which is restricted and added to the HLA antigen is allowed to act, and the amount of various cytokines (eg, IFN- ⁇ ) produced by the reaction of the CTL is measured by, for example, an ELIS ⁇ method.
- the candidate gene is a DNA encoding a tumor antigen protein. Since cyclophilin B has a tumor antigen peptide portion restricted to HLA-A24 and HLA-A2, the DNA encoding the HLA antigen is HLA-A24 cDNA (Cancer Res. , 55: 4248-4252 (1995), Genbank Accession No.M64740) and the cDNA of HLA-A2 (Genbank
- Examples of the CTL include those prepared from human peripheral blood lymphocytes, and CTLs such as KG-CTL (FERM BP-6725).
- the present invention also includes an antibody that specifically binds to the tumor antigen peptide of the present invention or a derivative thereof.
- the antibody is, for example, Antibodies; A Laboratory Manual, Lane, H, D. et al., Cold Spring Harber Laboratory Press New
- an antibody that recognizes the tumor antigen peptide or a derivative thereof, and furthermore, an antibody that neutralizes the activity thereof, can be easily obtained by appropriately immunizing an animal using the tumor antigen peptide or the derivative thereof of the present invention in a usual manner.
- Antibody applications include affinity chromatography Luffy, immunological diagnosis and the like.
- the antibody is appropriately labeled as necessary, and a sample obtained from a patient suspected of having a tumor (eg, blood, fl Etc.) to detect the presence of an antigen in the tumor, the presence or absence of a tumor can be diagnosed.
- a tumor eg, blood, fl Etc.
- it can be appropriately selected from an immunoplot method, a radioimmunoassay method (RIA), an enzyme immunoassay method (ELISA), a fluorescence or luminescence measurement method, or the like.
- the tumor antigen peptide or its derivative, or the tumor antigen protein (cyclophilin B) or its gene of the present invention can be used in vitro in the treatment of tumor patients as follows.
- the present invention provides a complex of an HLA antigen and the tumor antigen peptide of the present invention or a derivative thereof on the surface of an isolated cell having the ability to present antigen derived from a tumor patient. It is intended to provide an antigen-presenting cell and a therapeutic agent for a tumor comprising the antigen-presenting cell as an active ingredient.
- the “cells having antigen presenting ability” are not particularly limited as long as they are cells expressing an HLA antigen capable of presenting the tumor antigen peptide of the present invention or a derivative thereof on the cell surface.
- dendritic cells which are said to have high antigen-presenting ability are preferred.
- the substance added to prepare the antigen-presenting cell of the present invention from the cell having the antigen-presenting ability includes not only the tumor antigen peptide of the present invention or its derivative, but also the tumor antigen protein cyclophilin B.
- the gene may be used.
- the antigen-presenting cell of the present invention can be prepared not only for cyclophilin B and its gene, but also for its full-length polypeptide and its gene. At that time, when used in the form of protein or gene, it is necessary to be taken into cells. For this, refer to the section on therapeutic or prophylactic agents for tumors containing the gene and protein as active ingredients.
- the antigen-presenting cells of the present invention are obtained by isolating cells having antigen-presenting ability from patients with fl severity, and adding the tumor antigen peptides or derivatives thereof or tumor antigen proteins of the present invention to the cells. By pulsing the protein or its partial polypeptide outside the body to form a complex of the HLA antigen and the tumor antigen peptide or a derivative thereof (Cancer Immunol. Immunother., 46:82, 1998, J. Am. Immunol., 158: pl796, 1997, Cancer Res., 59: pi 184, 1999).
- dendritic cells When dendritic cells are used, for example, lymphocytes are separated from peripheral blood of tumor patients by the Ficoll method, non-adherent cells are removed, and adherent cells are cultured in the presence of GM-CSF and IL-4.
- the antigen-presenting cells of the present invention can be prepared by inducing dendritic cells, culturing the dendritic cells together with the fl severing antigen peptide of the present invention or a tumor antigen protein and pulsing the cells. See Example 13 for details.
- the antigen-presenting cell of the present invention is prepared by introducing a gene encoding the tumor antigen protein of the present invention or a partial polypeptide thereof into the cell having the antigen-presenting ability, It may be in the form of DNA or RNA. Specifically, in the case of DNA, it can be performed with reference to Cancer Res., 56: p5672, 1996 and J. Immunol., 161: ⁇ 5607, 1998, and in the case of RNA, J. Exp. Med., 184: p465, 1996.
- the therapeutic agent for tumors containing the antigen-presenting cells as an active ingredient preferably contains physiological saline, phosphate buffered saline (PBS), a medium, and the like in order to stably maintain the antigen-presenting cells.
- the administration method includes intravenous administration, subcutaneous administration, and intradermal administration.
- the in vitro use of the tumor antigen peptide or derivative thereof, or the tumor antigen protein or gene thereof of the present invention includes the following use in adoptive immunotherapy.
- tumor antigen peptide of the present invention or a derivative thereof, or a tumor antigen protein or a gene thereof to stimulate peripheral blood lymphocytes of a patient in vitro to increase ⁇ -lesion-specific CTL
- Therapies that return this CTL to the patient may be useful.
- the present invention also provides a CTL that specifically recognizes a complex of the HL ⁇ antigen and the tumor antigen peptide of the present invention or a derivative thereof, and a therapeutic agent for a tumor comprising the CTL as an active ingredient.
- the therapeutic agent preferably contains physiological saline, phosphate buffered saline (PBS), a medium and the like in order to stably maintain CTL.
- Administration methods include intravenous administration, subcutaneous administration, and intradermal administration.
- the tumor antigen protein, fl sever antigen peptide and derivatives thereof of the present invention can also be used as an active ingredient of a diagnostic agent for diagnosing a tumor. That is, the presence of an antibody in a sample (eg, blood, tumor tissue, etc.) obtained from a patient suspected of a tumor is detected by using the tumor antigen protein, the tumor antigen peptide or a derivative thereof itself as a diagnostic agent according to the present invention. Thus, early detection, recurrence, and metastasis of a tumor can be diagnosed. It can also be used for selecting tumor patients to which a drug containing the tumor antigen protein, tumor antigen peptide or the like of the present invention as an active ingredient can be applied. Specifically, the diagnosis can be made by using an immunoblot method, RIA, ELISA, fluorescence or luminescence measurement method, or the like.
- Tumor of the present invention The complex of the tumor antigen peptide or its derivative and the HLA antigen is subjected to the above-mentioned detection method, and fl swelling antigen-specific CTLs can be detected to diagnose early detection, recurrence and metastasis of fl swelling. it can.
- the present invention can also be used for selecting a tumor patient to which a medicine containing the tumor antigen protein, tumor antigen peptide or the like of the present invention as an active ingredient can be applied, and for judging the therapeutic effect of the medicine. That is, the present invention also provides a diagnostic agent for fl severe swelling, which comprises the tumor antigen peptide of the present invention or a derivative thereof as a part of an active ingredient.
- a tetramer of a complex of a fluorescently labeled HLA antigen and a tumor antigen peptide was prepared, and this was used for tumor formation.
- the above diagnosis can be made by quantifying the antigen peptide-specific CTL in the peripheral blood lymphocytes of the suspected patient by a single site meter.
- the present invention also provides KG-CTL (Accession No. FERM BP-6725), which is a CTL established from intratumoral infiltrating lymphocytes derived from lung adenocarcinoma. It has been clarified that the KG-CTL reacts with HLA-A24 and ⁇ LA-A2 positive cancer cell lines, and the cyclophilin B of the present invention also uses the reactivity with the KG-CTL as an index. Is a tumor antigen protein found by Therefore, by using KG-CTL, a new tumor antigen protein and tumor antigen peptide can be found in the same manner as cyclophilin B. Specifically, see Example 2 described later.
- FIG. 1 shows that the tumor antigen peptide of the present invention “84-92 (SEQ ID NO: 1) was introduced into C0S-7 cells transfected with HLA-A2402 cDNA recombinant plasmid or HLA-A2601 cDNA recombinant plasmid.
- FIG. 11 is a graph showing the results of measuring the amount of IFN- ⁇ produced by KG-CTL after culturing with KG-CTL after adding KG-CTL. The horizontal axis indicates the concentration of the added peptide, and the vertical axis indicates the amount of IFN produced by KG-CTL.
- FIG. 10 is a graph showing the results of measuring the amount of IFN- ⁇ produced by KG-CTL after culturing with KG-CTL after adding KG-CTL.
- the horizontal axis is the peptide concentration added, and the vertical axis is Shows the amount of IFN-y produced by KG-CTL.
- CTL cytotoxic T cell
- TIL intratumoral infiltrating lymphocytes
- lymphocyte culture medium After the surgical specimen of a lung adenocarcinoma patient was minced in a culture solution, the cells were dispersed by stirring in a culture solution containing collagenase and DNAase. Lymphocytes were separated from the cell dispersion by specific gravity centrifugation using Ficoll Conray solution. For lymphocytes, use a 24-well plate, 45% RPMI-1640, 45% AIM-V (GIBCO BRL), 10% FCS, lOOU / ml interleukin_2, 0. ImM NEAA (GIBCO BRL) ) was added to the culture medium (hereinafter referred to as lymphocyte culture medium).
- KG-CTL KG-CTL
- the reactivity of KG-CTL against various cancer cell lines was determined by inoculating 1 ⁇ 10 4 cancer cell lines in a 96-well plate, adding 1 ⁇ 10 5 KG-CTL to the next day, and adding 18 holes.
- IFN- ⁇ interferon- ⁇
- ELISA Enzymim Noassy
- HT-1376 (bladder cancer cell line) 4608 2402/2402 1-87 (lung cancer cell line) 194 0207/1101 11-18 (lung cancer cell line) 4632 0201/2402 PC-9 (lung cancer cell line) 1102 0206/2402 LC -1 (lung cancer cell line) 129 3101/3302 YT-803 (lung cancer cell line) 285 3101/3302 143B (osteosarcoma cell line) 1547 0211/0211 None (KG-CTL only) 100
- KG-CTL strongly reacts with HLA-A2402-positive cancer cells (HT-1376, 11-18, PC-9) in the table to produce IFN- ⁇ , and HLA- ⁇ 2 It was also shown to produce IFN-o / in response to positive cancer cells (143 ⁇ ) _. Also, from the results in Table 3, KG-CTL is a B cell line or leukemia cell line transformed with the HLA-A2402-positive EB virus.
- SSB SSB, MT-2
- HPB-MLT HLA-A2-positive leukemia cells
- a cDNA library was prepared from the bladder cancer cell line HT-1376 (ATCCII- ⁇ CRL1472) to which KG-CTL strongly reacted in Example 1 by the following method.
- Electromax DH10B TM cell (GIBCO BRL) by electric pulse using Gene Pulser (Bio-Rad), and LB medium (50 g / ml) containing ampicillin (50 g / ml) was introduced.
- Transformants into which the recombinant plasmid had been introduced were selected with 1% batato tryptone, 0.5% yeast extract, 0.5% NaCl, pH 7.3).
- Recombinant plasmid DNA of a transformant cultured in a TYGPN medium was prepared in a microplate by an Alkali lysis method (edited by FM Ausubel et al., CURRENT PR0TC0LS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc.).
- the recombinant plasmid DNA recovered by isopropanol precipitation was suspended in 50 ⁇ l of a 10 mM Tris, Im EDTA, pH 7.4 solution containing 20 ng / ml RNase.
- HLA-A2402 (Genbank Accession) as described in 4 25 2 (19995) No. M64740) and HLA-A2601 cDNA were inserted into an expression vector pCR3 (manufactured by INVITROGEN) to produce a recombinant plasmid.
- the recombinant plasmid of HT-1376c DNA and the recombinant plasmid of HLA-A2402c DNA were double-transfected into the cell line COS-7 (ATCC number CRL1651) derived from the kidney of African green monkey by the lipofectin method as follows. Ect. That is, C0S-7 was added to a 96-well flat-bottomed microplate at 8000 cells per well, and cultured in RPMI1640 medium containing 100 ⁇ l of 10% FCS for 1 day.
- lipofectamine reagent GIBCO BRL
- recombinant plasmid 25/1 for HT-1376 cDNII and recombinant plasmid HLA-A2402c DNA for about 100 transformants 10/1 (200 ng) and a mixed solution 701 of lipofectin reagent 35 // 1 diluted approximately 50-fold, 30 ⁇ 1 was added to C0S-7, and double transfection was performed. Two transfectants were prepared.
- a pool of transformants was spread on a plate of LB agar medium containing ampicillin (50 / g / ml) to obtain colonies, and each group contained 400 transformants per transformant.
- the cells were cultured in the same manner as described above under various conditions to prepare a recombinant plasmid DNA of HT-1376c DNA.
- double transfection of the recombinant plasmid of HT-1376 cDNA and the recombinant plasmid of HLA-A2402c DNA into C0S-7 was performed in the same manner as above, followed by mixed culture with KG-CTL.
- the nucleotide sequence of the plasmid was determined using a plasmid clone 4F2 coding for the tumor antigen protein obtained in Example 2 (DyeDeoxy Terminator Cycle Sequencing Kit, manufactured by Nokikin Enorema Co., Ltd.).
- the nucleotide sequence of plasmid clone 4F2 was registered in Genbank Accession No.M60857. It was identical to the amino acid sequence of Human cyclophilin B.
- the sequence of cyclophilin B is:
- the cyclophilin B is a binding protein of cyclosporin A, which is an immunosuppressant, and is known to be involved in activation of immune cells in vivo. According to Example 2 described above, it became clear for the first time that cyclophilin B, which was known only to be involved in the activation of immune cells, has a function as a tumor antigen protein.
- Example 4
- the sequence of the antigen peptide presented by binding to the HLA molecule has a regularity (motif) force S.
- the second position of the peptide consisting of 8 to 11 amino acids is tyrosine, phenylalanine, methionine or tryptophan.
- phenylalanine, tryptophan, leucine, isoleucine or methionine at the C-terminus is motivated (I band nogenetics, 41: 178, 1995, J. Immunol., 152: 3913, 1994, J. Immunol., 155: 4307, 1994).
- HLA-A0201 is a peptide consisting of leucine or methionine
- C-terminal is valine or leucine
- HLA-A0204 is a peptide consisting of leucine and C-terminal Is leucine
- in HLA-A0205 the second position is palin, leucine, isoleucine or methionine
- in the C-terminus is leucine
- in HLA-A0206 the second position is palin or glutamine
- the C-terminus is valine or leucine
- HLA-A0207 the second position is leucine and the C-terminus is leucine.
- a peptide portion consisting of 811 amino acids having the above motif was selected.
- the selected peptides having the binding motif of HLA-A24 are shown in SEQ ID NOs: 1 to 11, and the peptides having the binding motif of HLA-A2 are shown in SEQ ID NOs: 12 to 36. These peptides were requested to Biologica and synthesized by the Fmoc method.
- HLA- A2402 cDNA recombinant plasmid literature According (J. Exp Med 187.. 277 , 1998) described, and trans Hue Kushiyon at Ripofuekuchin method 10 4 COS- 7 cells HLA- A2402 was expressed.
- the cells were pulsed with 10 / M of each peptide having the binding motif of HLA-A24 synthesized previously for 2 hours, and then cultured with 2 ⁇ 10 4 KG-CTLs for 18 hours.
- CTL culture supernatant produced by CTL
- the amount of IFN- ⁇ was measured by ELISA.
- two kinds of peptides namely, a peptide consisting of the sequence of amino acids 84 to 92 of the amino acid sequence of cyclophilin (SEQ ID NO: 1, hereinafter, the peptide is simply referred to as “84-92”)
- a peptide consisting of the sequence from position 91 to position 99 SEQ ID NO: 2, hereinafter, this peptide may be simply referred to as “91-99” was subjected to the following experiments.
- Resin is Fmo c _P he— A 1 ko Re sin (0.56mmo 1/1 00-20 Ome sh) was used. Using 100 mg of this resin, synthesis was started according to Schedule 1 described below, and Fmo c_A sp (O t Bu) -OH, Fmo c -Lys (B oc) -OH, Fmo c -I 1 e -OH , Fmo c—Val _OH, Fmo c—Ar g (Pmc) -OH, Fmo c -H is (T rt) -OH, Fmoc -Phe -OH, Fmoc— Lys (Boc) — ⁇ H were coupled sequentially. After the coupling, the process was performed up to step 3 of schedule 1 shown in Table 5 below, and as a result, a peptide resin was obtained.
- the peptide resin Re agent K (5% phenol, 5% thiophosphite two sole, 5% H 2 O, 2.5% Etanjichioru ZT FA solution) 2 m 1 was added, and the 2.5 hours at room temperature Was. 10 ml of getyl ether was added to the reaction mixture under ice cooling, and the mixture was stirred for 10 minutes, filtered, and washed with 10 ml of getyl ether. 10 ml of a 10% aqueous acetic acid solution (hereinafter referred to as acetic acid aqueous solution) was added to the filtered product, and after stirring for 30 minutes, the resin was separated by filtration and washed with 4 ml of aqueous acetic acid.
- acetic acid aqueous solution a 10% aqueous acetic acid solution
- the obtained crude peptide was dissolved in acetic acid water, and a reversed-phase packing material COSMOS IL 5 C 18 — AR column (250 x 250 mm) previously equilibrated with 0.1% TFA water ), And the column was washed with 0.1% TFA water.
- the acetonitrile concentration was increased to 25% in 260 minutes, and the column was eluted at a flow rate of ymlZmin.
- the eluate was monitored at A220 nm, the fractions containing the target compound were collected, lyophilized, and Lys-Phe-His-Arg-Va1-I1e-Lys-Asp-Ph-Ph e 1.7 mg was obtained.
- Ph is a linear gradient of acetonitrile containing 0.1% TFA from 0% to 60% using a reversed-phase YMC—PACK ODS—AM column (4.6 ⁇ X 250 mm). Analysis by the elution method showed a retention time of 23.9 minutes, and the amino acid analysis value and the mass analysis value were consistent with the theoretical values.
- the obtained crude peptide was dissolved in aqueous acetic acid, and applied to a reverse-phase packing material CO S MOS IL 5C 18-AR column (25 ⁇ X 250 mm) preliminarily equilibrated with 0.1% TF water. After injection and washing the column with 0.1% TFA water, the concentration of acetonitrile was increased to 31% in 260 minutes, and eluted at a flow rate of 7 ml / min. Monitor the eluate at A 220 nm, collect the fractions containing the target, lyophilize, and run Asp-Phe-Met-I1e_Gln-GlyGly-Asp-Phe3. 6 mg were obtained.
- the obtained Asp-Phe-Met-I1e-G1n-G1y_Gly_Asp—Phe is a reversed-phase packing material YMC—PACK ODS—AM column (4.6 ⁇ ⁇ 250 Analysis of acetonitrile containing 0.1% TFA from 0% to 60% using a linear gradient elution method showed a retention time of 25.8 minutes, and the amino acid analysis value (where Me (Not detected) and mass spectrometry values were consistent with the theoretical values.
- Example 4 The same experiment as in Example 4 was performed for the two peptides synthesized in Examples 5 and 6 above, with peptide concentrations ranging from 0.001 to 1000 / g / ml. It was revealed that it functions as a peptide.
- Fig. This is shown in Figure 1 and Figure 2. In the figure, the horizontal axis shows the peptide concentration (pg / ml), and the vertical axis shows the amount of IFN- ⁇ (pg / ml) produced by KG-CTL.
- Lys—Tyr—His-Arg ⁇ Va1-1 I1e-Lys-Asp—Phe is a reversed-phase packing material YMC—PACK ODS—AM column (4.6 ⁇ X Analysis of acetonitrile containing 0.1% TFA from 0% to 60% using a linear gradient elution method showed a retention time of 17.7 minutes. Was in agreement with the theoretical value.
- the obtained crude peptide was dissolved in aqueous acetic acid, and injected into a COSMOS IL 5C18-AR column (250 x 250 mm), which had been equilibrated with 0.1% TF water beforehand. After washing the column with 0.1% TFA water, the concentration of acetonitrile was increased to 27% in 200 minutes, and eluted at a flow rate of 7 ml. Monitor the eluate at A 220 nm, collect the fraction containing the target substance, freeze-dry, and run Asp-Tyr-Met-I1e-GlnGlyGly-Asp-Phe. 12.8 mg was obtained.
- Asp-Tyr-Met-I1e—Gln—Gly—Gly—Asp—Phe is a reversed-phase packing material YMC—PACK ODS—AM column (4.6 ⁇ X Analysis of acetonitrile containing 0.1% TFA from 0% to 60% using a linear gradient elution method showed a retention time of 24.7 minutes. Was not detected) and the mass spectrometry values were consistent with the theoretical values.
- Lymphocytes were isolated from peripheral blood of leukemia patients with HLA--locus ⁇ 24 heterozygous cells by the Ficoll method. Phosphorus in a 24-well plate with 2 x 10 6 cell holes Papillocytes were added and cultured in a lymphocyte culture solution. The tumor antigen peptide was added to the culture solution to 10 ⁇ to stimulate peripheral blood lymphocytes. After one week, in addition to with X-ray irradiation (50 G y) was approximately 2 X 1 0 5 or peripheral blood lymphocytes comprising the tumor antigen peptide in 1 0 Myumyu, was performed a second stimulus. One week later, the third stimulation was repeated in the same manner. One week after the third stimulation, the cultured lymphocytes were collected.
- Peripheral blood lymphocytes stimulated with peptides 84-92, 84-92'2F- ⁇ , 91-99 and 91-99.2F- ⁇ are converted to HLA- ⁇ 24-positive BEC-2. It reacted but did not react with HLA- ⁇ 24-negative Ban-B1, indicating that HLA-A24-restricted antigen-peptide-specific CTL was induced.
- Peripheral blood lymphocytes stimulated with the 84-92'2F-Y and 91-99'2F-Y peptides were also stimulated with the 84-92 and 91-99 peptides.
- the expression plasmid was introduced into COS-7 cells (ATCC No. CRL1651) or VA-13 cells (RIKEN Cell Bank), and the cells were pulsed with the peptide and used in this experiment.
- a similar experiment can be performed by introducing the HLA-A2402 cDNA expression plasmid into the C0S-7 cells or VA-13 cells and using the cells not pulsed with the peptide instead of Ban-B1. Is possible
- Examples 1 to 10 revealed that cyclophilin B was an 8-fold ulcer antigen protein, the following describes cyclophilin, cyclophilin C and cyclophilin D, which are known as cyclophilin B homologues. It was examined whether the same activity exists.
- the resin is Fmo c— P He—A 1 k o R e s i n (0.67 mm o 1 / g, 10
- the obtained peptide was dissolved in aqueous acetic acid, and the reversed phase filler YMC—PACK ODS—ASH—363—5 (5%) previously equilibrated with 0.1% TFA water After washing the column with 0.1% TFA water, the acetonitrile concentration was increased from 0% to 15% for 60 minutes and from 15% to 30% for 240 minutes.
- the 9 eluates eluted at a flow rate of 7 m 1 / min are monitored at 220 nm, the fractions containing the target compound are collected, freeze-dried, and G 1y—P he -Me t—Cys—G 1 n_Gly — 9.7 mg of —Gly—Asp—Phe was obtained.
- Example 11 Using the three peptides synthesized in Example 11, it was examined whether antigen-specific CTL could be induced from peripheral blood lymphocytes. Lymphocytes were isolated from peripheral blood of a healthy individual homozygous for HLA-A Lokasca SA24 by the Ficoll method. Lymphocytes were stimulated three times with the above peptide in the same manner as in Example 10. One week after the third stimulation, the lymphocytes were collected, and HLA-A24-positive T cells labeled with sl Cr were labeled according to the method described in DDKharkevitch et al., Int. J. Cancer, 58: 317 (1994). Cytotoxic activity was measured using lymphoma-derived cell lines K0PT-K1 and HLA-A24-negative T-cell leukemia cell line RPMI8402 as target cells. Table 9 shows the results.
- the HLA antigen and the cyclophilin-derived tumor antigen peptide can be ligated.
- An antigen-presenting cell on which the complex is presented can be prepared. Whether or not the desired antigen-presenting cells have been prepared can be examined by using as an index whether or not the antigen-presenting cells can induce antigen-specific CTL from peripheral blood lymphocytes.
- peripheral blood of a healthy person will be described, but it is needless to say that antigen-presenting cells can be prepared by a similar method using peripheral blood of a tumor patient.
- lymphocytes are separated from peripheral blood of HLA-A24-positive healthy persons by the Ficoll method. After leaving the lymphocytes in the culture flask at 37 ° C for 3 hours, remove non-adherent cells. The adherent cells are cultured for 7 days in the presence of GM-CSF (2000 U / ml) and IL-4 (2000 U / ml) to induce dendritic cells known as cells having high antigen presenting ability. The collected dendritic cells were incubated at 37 ° C. with 10 ⁇ g / ml of the tumor antigen peptide of the present invention or 100 ⁇ g / ml of the tumor antigen protein (cyclophilin) of the present invention or a partial polypeptide thereof.
- GM-CSF 2000 U / ml
- IL-4 2000 U / ml
- CD8 + T cells prepared from the healthy human peripheral blood lymphocytes using Biomagnetic Separation Beads (Dynal) and dendritic cells pulsed with the peptide or protein in a 24-well plate Perform mixed culture and stimulate antigen. The day after stimulation, IL-2 (100 U / ml) is added. Approximately once a week, similarly, stimulate T cells using dendritic cells pulsed with the peptide or protein (2-4 times). One week after the last stimulation, the cultured T cells are collected.
- BEC-2 a B cell line expressing the tumor antigen protein of the present invention and transformed with HLA-A24-positive EB virus, and HLA-A24 expressing the tumor antigen protein of the present invention
- Ban-Bl a B cell strain transformed with the negative EB virus, as target cells
- the T cell reactivity was measured by ELISA for the amount of IFN-T in the culture supernatant in the same manner as in Example 10.
- the cytotoxic activity on target cells labeled with 51 Cr is measured.
- antigen-specific CTLs are induced, a reaction is observed only for BEC-2.
- HLA-A2402 cDNA (Genbank Accession No. M64740) expression plasmid was transferred to COS-7 cells (ATCC No. CRL1651) and VA-13 cells (RIKEN cells). Cells that were introduced into the bank and pulsed with the tumor antigen peptide or tumor antigen protein of the present invention, and in place of Ban-B1 used in this experiment,
- the second amino acid in the amino acid sequence set forth in SEQ ID NO: 37 is phenylalanine, tyrosine, methiophan or tryptophan, and the ninth amino acid is fenii / lealanine, leucine, isoleucine, tryptophan or methiophan. Nin.
- the second amino acid in the amino acid sequence set forth in SEQ ID NO: 38 is phenylalanine, tyrosine, methionine or tryptophan, and the ninth amino acid is fenyarayun, leucine, isoleucine, tryptophan or methionine. It is.
- a cyclophilin-derived JB tumor antigen peptide and a derivative thereof having functionally equivalent properties can be obtained in vivo.
- tumor therapeutic agents utilized in V0 or i n vitro, Ru can provide such prophylactic or diagnostic agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43926/99A AU749544B2 (en) | 1998-06-25 | 1999-06-24 | Tumor antigen peptides originating in cyclophilin B |
NZ508996A NZ508996A (en) | 1998-06-25 | 1999-06-24 | Tumor antigen peptides derived from cyclophilin B |
CA002331761A CA2331761A1 (en) | 1998-06-25 | 1999-06-24 | Tumor antigen peptides originating in cyclophilin b |
JP2000555939A JP4413429B2 (ja) | 1998-06-25 | 1999-06-24 | サイクロフィリンb由来の腫瘍抗原ペプチド |
EP99926783A EP1090924B8 (en) | 1998-06-25 | 1999-06-24 | Tumor antigen peptides originating in cyclophilin b |
DE69937294T DE69937294T2 (de) | 1998-06-25 | 1999-06-24 | Von cyclophilin b abstammende tumorantigen-peptide |
US09/720,469 US7041297B1 (en) | 1998-06-25 | 1999-06-24 | Tumor antigen peptides originating in cyclophilin B |
HK04109605A HK1067645A1 (en) | 1998-06-25 | 2004-12-03 | Tumor antigen peptides originating in cyclophilin b |
US11/227,238 US7368107B2 (en) | 1998-06-25 | 2005-09-16 | Tumor antigen peptides derived from cyclophilin B |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17844998 | 1998-06-25 | ||
JP10/178449 | 1998-06-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09720469 A-371-Of-International | 1999-06-24 | ||
US11/227,238 Division US7368107B2 (en) | 1998-06-25 | 2005-09-16 | Tumor antigen peptides derived from cyclophilin B |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999067288A1 true WO1999067288A1 (fr) | 1999-12-29 |
WO1999067288A9 WO1999067288A9 (fr) | 2000-03-30 |
Family
ID=16048723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/003360 WO1999067288A1 (fr) | 1998-06-25 | 1999-06-24 | Peptides d'antigenes tumoraux provenant de la cyclophiline b |
Country Status (15)
Country | Link |
---|---|
US (2) | US7041297B1 (ja) |
EP (1) | EP1090924B8 (ja) |
JP (1) | JP4413429B2 (ja) |
KR (1) | KR100653590B1 (ja) |
CN (1) | CN1318447C (ja) |
AT (1) | ATE375362T1 (ja) |
AU (1) | AU749544B2 (ja) |
CA (1) | CA2331761A1 (ja) |
DE (1) | DE69937294T2 (ja) |
ES (1) | ES2294844T3 (ja) |
HK (1) | HK1067645A1 (ja) |
ID (1) | ID27788A (ja) |
NZ (1) | NZ508996A (ja) |
TW (1) | TWI228128B (ja) |
WO (1) | WO1999067288A1 (ja) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105306B1 (en) * | 2000-08-10 | 2006-09-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for modulating somatolactogenic functions |
WO2007126160A1 (ja) | 2006-05-01 | 2007-11-08 | Hitachi Chemical Company, Ltd. | プロスタシン部分ペプチド及び抗プロスタシン抗体 |
WO2008099908A1 (ja) | 2007-02-16 | 2008-08-21 | Oncotherapy Science, Inc. | 脈絡膜新生血管のワクチン療法 |
WO2008126413A1 (en) | 2007-04-11 | 2008-10-23 | Oncotherapy Science, Inc. | Tem8 peptides and vaccines comprising the same |
EP2014679A1 (en) | 2002-09-12 | 2009-01-14 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
WO2009028581A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
WO2009153992A1 (en) | 2008-06-19 | 2009-12-23 | Oncotherapy Science, Inc. | Cdca1 epitope peptides and vaccines containing the same |
WO2010095428A1 (en) | 2009-02-18 | 2010-08-26 | Oncotherapy Science, Inc. | Foxm1 peptides and vaccines containing the same |
WO2010106770A1 (en) | 2009-03-18 | 2010-09-23 | Oncotherapy Science, Inc. | Neil3 peptides and vaccines including the same |
WO2010137295A1 (en) | 2009-05-26 | 2010-12-02 | Oncotherapy Science, Inc. | Cdc45l peptides and vaccines including the same |
WO2011074236A1 (en) | 2009-12-14 | 2011-06-23 | Oncotherapy Science, Inc. | Tmem22 peptides and vaccines including the same |
WO2011111392A1 (en) | 2010-03-11 | 2011-09-15 | Oncotherapy Science, Inc. | Hjurp peptides and vaccines including the same |
EP2468886A1 (en) | 2006-12-13 | 2012-06-27 | Oncotherapy Science, Inc. | TTK as tumor marker and therapeutic target for lung cancer |
WO2013018690A1 (ja) | 2011-07-29 | 2013-02-07 | 国立大学法人徳島大学 | Erap1由来ペプチド及びその使用 |
WO2013024582A1 (en) | 2011-08-12 | 2013-02-21 | Oncotherapy Science, Inc. | Mphosph1 peptides and vaccines including the same |
WO2013061594A1 (en) | 2011-10-28 | 2013-05-02 | Oncotherapy Science, Inc. | Topk peptides and vaccines including the same |
WO2014010231A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Kif20a epitope peptides for th1 cells and vaccines containing the same |
WO2014010232A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Ly6k epitope peptides for th1 cells and vaccines containing the same |
WO2014041784A1 (en) | 2012-09-11 | 2014-03-20 | Oncotherapy Science, Inc. | Ube2t peptides and vaccines containing the same |
WO2014141683A1 (en) | 2013-03-12 | 2014-09-18 | Oncotherapy Science, Inc. | Kntc2 peptides and vaccines containing the same |
EP2801367A1 (en) | 2007-09-18 | 2014-11-12 | Green Peptide Co., Ltd. | CTL inducer composition |
EP3219720A2 (en) | 2008-12-05 | 2017-09-20 | Onco Therapy Science, Inc. | Wdrpuh epitope peptides and vaccines containing the same |
US10137183B2 (en) | 2013-10-21 | 2018-11-27 | Taiho Pharmaceutical Co., Ltd. | Peptide compositions having 4 linked CTL epitopes and uses thereof |
WO2020004622A1 (ja) | 2018-06-29 | 2020-01-02 | 大鵬薬品工業株式会社 | 抗腫瘍剤及びその評価方法 |
EP3590954A2 (en) | 2014-08-04 | 2020-01-08 | OncoTherapy Science, Inc. | Koc1-derived peptide and vaccine including same |
WO2020027239A1 (ja) | 2018-08-02 | 2020-02-06 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
WO2020111167A1 (ja) | 2018-11-30 | 2020-06-04 | 国立大学法人徳島大学 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
WO2021132550A1 (ja) | 2019-12-26 | 2021-07-01 | 大鵬薬品工業株式会社 | 術後補助療法剤 |
EP3848383A2 (en) | 2014-08-04 | 2021-07-14 | Oncotherapy Science, Inc. | Urlc10-derived peptide and vaccine containing same |
EP4219525A2 (en) | 2015-10-08 | 2023-08-02 | OncoTherapy Science, Inc. | Foxm1-derived peptide, and vaccine including same |
EP4282883A2 (en) | 2014-08-04 | 2023-11-29 | OncoTherapy Science, Inc. | Cdca1-derived peptide and vaccine containing same |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7652000A (en) * | 1999-09-10 | 2001-04-17 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Ant-1 as drug target |
CA2397863A1 (en) * | 2000-01-24 | 2001-07-26 | Trustees Of Tufts College | Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
US6642270B2 (en) | 2000-05-15 | 2003-11-04 | Paratek Pharmaceuticals, Inc. | 7-substituted fused ring tetracycline compounds |
WO2001098236A2 (en) * | 2000-06-16 | 2001-12-27 | Trustees Of Tufts College | 7-phenyl-substituted tetracycline compounds |
AU2002365120A1 (en) | 2001-08-02 | 2003-07-15 | Paratek Pharmaceuticals, Inc. | Medicaments |
US20080254445A1 (en) * | 2003-09-22 | 2008-10-16 | Kyogo Itoh | Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent |
TWI261038B (en) * | 2004-08-11 | 2006-09-01 | Bo-Cheng Chen | Bicycle gear-shifting handgrip |
CA2585418A1 (en) * | 2004-10-25 | 2006-05-04 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
US8440646B1 (en) | 2006-10-11 | 2013-05-14 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of Bacillus anthracis infections |
CA2706475C (en) | 2007-11-29 | 2016-05-03 | Actelion Pharmaceuticals Ltd | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
CN115078727A (zh) * | 2022-07-13 | 2022-09-20 | 首都医科大学附属北京胸科医院 | 一种预测癌症免疫治疗效果的标志物、试剂盒与应用 |
DE102022118517A1 (de) | 2022-07-25 | 2024-01-25 | Dennis Reitmeir | Liegestützvorrichtung mit drehbaren Griffeinheiten |
CN115372618A (zh) * | 2022-09-19 | 2022-11-22 | 首都医科大学附属北京胸科医院 | 一种检测蛋白标志物水平的试剂在制备用于评估肿瘤治疗效果的诊断产品中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08500106A (ja) * | 1992-08-07 | 1996-01-09 | サイテル コーポレイション | Hla結合性ペプチド及びその用途 |
JPH09151200A (ja) * | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0326067A3 (en) * | 1988-01-26 | 1991-04-17 | The Du Pont Merck Pharmaceutical Company | Use of cyclophilin as an anti-inflammatory and immunomodulatory agent |
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
-
1999
- 1999-06-24 AT AT99926783T patent/ATE375362T1/de not_active IP Right Cessation
- 1999-06-24 ES ES99926783T patent/ES2294844T3/es not_active Expired - Lifetime
- 1999-06-24 CN CNB998098566A patent/CN1318447C/zh not_active Expired - Lifetime
- 1999-06-24 JP JP2000555939A patent/JP4413429B2/ja not_active Expired - Lifetime
- 1999-06-24 CA CA002331761A patent/CA2331761A1/en not_active Abandoned
- 1999-06-24 US US09/720,469 patent/US7041297B1/en not_active Expired - Fee Related
- 1999-06-24 KR KR1020007014760A patent/KR100653590B1/ko not_active IP Right Cessation
- 1999-06-24 EP EP99926783A patent/EP1090924B8/en not_active Expired - Lifetime
- 1999-06-24 WO PCT/JP1999/003360 patent/WO1999067288A1/ja active IP Right Grant
- 1999-06-24 ID IDW20002735A patent/ID27788A/id unknown
- 1999-06-24 DE DE69937294T patent/DE69937294T2/de not_active Expired - Lifetime
- 1999-06-24 NZ NZ508996A patent/NZ508996A/en unknown
- 1999-06-24 AU AU43926/99A patent/AU749544B2/en not_active Ceased
- 1999-06-25 TW TW088110697A patent/TWI228128B/zh not_active IP Right Cessation
-
2004
- 2004-12-03 HK HK04109605A patent/HK1067645A1/xx not_active IP Right Cessation
-
2005
- 2005-09-16 US US11/227,238 patent/US7368107B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08500106A (ja) * | 1992-08-07 | 1996-01-09 | サイテル コーポレイション | Hla結合性ペプチド及びその用途 |
JPH09151200A (ja) * | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
Non-Patent Citations (2)
Title |
---|
PRICE E R, ET AL.: "HUMAN CYCLOPHILIN B: A SECOND CYCLOPHILIN GENE ENCODES A PEPTIDYL-PROLYL ISOMERASE WITH A SIGNAL SEQUENCE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 88, 1 January 1991 (1991-01-01), US, pages 1903 - 1907, XP002919643, ISSN: 0027-8424, DOI: 10.1073/pnas.88.5.1903 * |
RAMMENSEE H-G, FRIEDE T, STEVANOVIC S: "MHC LIGANDS AND PEPTIDE MOTIFS: FIRST LISTING", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 41, 1 January 1995 (1995-01-01), DE, pages 178 - 228, XP002919644, ISSN: 0093-7711, DOI: 10.1007/BF00172063 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105306B1 (en) * | 2000-08-10 | 2006-09-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for modulating somatolactogenic functions |
EP2261249A2 (en) | 2002-09-12 | 2010-12-15 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2270041A2 (en) | 2002-09-12 | 2011-01-05 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2014679A1 (en) | 2002-09-12 | 2009-01-14 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2014678A2 (en) | 2002-09-12 | 2009-01-14 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2270042A2 (en) | 2002-09-12 | 2011-01-05 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2267021A2 (en) | 2002-09-12 | 2010-12-29 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2267023A2 (en) | 2002-09-12 | 2010-12-29 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2267022A2 (en) | 2002-09-12 | 2010-12-29 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2261247A2 (en) | 2002-09-12 | 2010-12-15 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
EP2261248A2 (en) | 2002-09-12 | 2010-12-15 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
WO2007126160A1 (ja) | 2006-05-01 | 2007-11-08 | Hitachi Chemical Company, Ltd. | プロスタシン部分ペプチド及び抗プロスタシン抗体 |
EP2468886A1 (en) | 2006-12-13 | 2012-06-27 | Oncotherapy Science, Inc. | TTK as tumor marker and therapeutic target for lung cancer |
EP2468887A1 (en) | 2006-12-13 | 2012-06-27 | Oncotherapy Science, Inc. | TTK as tumor marker and therapeutic target for lung cancer |
WO2008099908A1 (ja) | 2007-02-16 | 2008-08-21 | Oncotherapy Science, Inc. | 脈絡膜新生血管のワクチン療法 |
WO2008126413A1 (en) | 2007-04-11 | 2008-10-23 | Oncotherapy Science, Inc. | Tem8 peptides and vaccines comprising the same |
EP2508601A2 (en) | 2007-04-11 | 2012-10-10 | Oncotherapy Science, Inc. | Tem8 peptides and vaccines comprising the same |
WO2009028581A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
EP2801367A1 (en) | 2007-09-18 | 2014-11-12 | Green Peptide Co., Ltd. | CTL inducer composition |
EP3494981A1 (en) | 2007-09-18 | 2019-06-12 | BrightPath Biotherapeutics Co., Ltd. | Ctl inducer composition |
US9642900B2 (en) | 2007-09-18 | 2017-05-09 | Green Peptide Co., Ltd. | CTL inducer composition |
EP3156061A1 (en) | 2007-09-18 | 2017-04-19 | Green Peptide Co., Ltd. | Ctl inducer composition |
US9102715B2 (en) | 2007-09-18 | 2015-08-11 | Green Peptide Co., Ltd. | CTL inducer composition |
WO2009153992A1 (en) | 2008-06-19 | 2009-12-23 | Oncotherapy Science, Inc. | Cdca1 epitope peptides and vaccines containing the same |
EP4047009A2 (en) | 2008-12-05 | 2022-08-24 | OncoTherapy Science, Inc. | Wdrpuh epitope peptides and vaccines containing the same |
EP3219720A2 (en) | 2008-12-05 | 2017-09-20 | Onco Therapy Science, Inc. | Wdrpuh epitope peptides and vaccines containing the same |
WO2010095428A1 (en) | 2009-02-18 | 2010-08-26 | Oncotherapy Science, Inc. | Foxm1 peptides and vaccines containing the same |
WO2010106770A1 (en) | 2009-03-18 | 2010-09-23 | Oncotherapy Science, Inc. | Neil3 peptides and vaccines including the same |
EP3556857A2 (en) | 2009-05-26 | 2019-10-23 | Oncotherapy Science, Inc. | Cdc45l peptides and vaccines including the same |
EP3868778A2 (en) | 2009-05-26 | 2021-08-25 | OncoTherapy Science, Inc. | Cdc45l peptides and vaccines including the same |
WO2010137295A1 (en) | 2009-05-26 | 2010-12-02 | Oncotherapy Science, Inc. | Cdc45l peptides and vaccines including the same |
EP3208334A2 (en) | 2009-05-26 | 2017-08-23 | Oncotherapy Science, Inc. | Cdc45l peptides and vaccines including the same |
WO2011074236A1 (en) | 2009-12-14 | 2011-06-23 | Oncotherapy Science, Inc. | Tmem22 peptides and vaccines including the same |
WO2011111392A1 (en) | 2010-03-11 | 2011-09-15 | Oncotherapy Science, Inc. | Hjurp peptides and vaccines including the same |
WO2013018690A1 (ja) | 2011-07-29 | 2013-02-07 | 国立大学法人徳島大学 | Erap1由来ペプチド及びその使用 |
WO2013024582A1 (en) | 2011-08-12 | 2013-02-21 | Oncotherapy Science, Inc. | Mphosph1 peptides and vaccines including the same |
WO2013061594A1 (en) | 2011-10-28 | 2013-05-02 | Oncotherapy Science, Inc. | Topk peptides and vaccines including the same |
EP3296317A1 (en) | 2011-10-28 | 2018-03-21 | OncoTherapy Science, Inc. | Topk peptides and vaccines including the same |
WO2014010232A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Ly6k epitope peptides for th1 cells and vaccines containing the same |
WO2014010231A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Kif20a epitope peptides for th1 cells and vaccines containing the same |
WO2014041784A1 (en) | 2012-09-11 | 2014-03-20 | Oncotherapy Science, Inc. | Ube2t peptides and vaccines containing the same |
WO2014141683A1 (en) | 2013-03-12 | 2014-09-18 | Oncotherapy Science, Inc. | Kntc2 peptides and vaccines containing the same |
US10137183B2 (en) | 2013-10-21 | 2018-11-27 | Taiho Pharmaceutical Co., Ltd. | Peptide compositions having 4 linked CTL epitopes and uses thereof |
EP3590954A2 (en) | 2014-08-04 | 2020-01-08 | OncoTherapy Science, Inc. | Koc1-derived peptide and vaccine including same |
EP3848383A2 (en) | 2014-08-04 | 2021-07-14 | Oncotherapy Science, Inc. | Urlc10-derived peptide and vaccine containing same |
EP3981416A2 (en) | 2014-08-04 | 2022-04-13 | OncoTherapy Science, Inc. | Koc1-derived peptide and vaccine including same |
EP4282883A2 (en) | 2014-08-04 | 2023-11-29 | OncoTherapy Science, Inc. | Cdca1-derived peptide and vaccine containing same |
EP4353321A2 (en) | 2014-08-04 | 2024-04-17 | OncoTherapy Science, Inc. | Koc1-derived peptide and vaccine including same |
EP4219525A2 (en) | 2015-10-08 | 2023-08-02 | OncoTherapy Science, Inc. | Foxm1-derived peptide, and vaccine including same |
WO2020004622A1 (ja) | 2018-06-29 | 2020-01-02 | 大鵬薬品工業株式会社 | 抗腫瘍剤及びその評価方法 |
WO2020027239A1 (ja) | 2018-08-02 | 2020-02-06 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
WO2020111167A1 (ja) | 2018-11-30 | 2020-06-04 | 国立大学法人徳島大学 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
WO2021132550A1 (ja) | 2019-12-26 | 2021-07-01 | 大鵬薬品工業株式会社 | 術後補助療法剤 |
Also Published As
Publication number | Publication date |
---|---|
AU749544B2 (en) | 2002-06-27 |
AU4392699A (en) | 2000-01-10 |
EP1090924B8 (en) | 2007-11-21 |
TWI228128B (en) | 2005-02-21 |
HK1067645A1 (en) | 2005-04-15 |
DE69937294D1 (de) | 2007-11-22 |
ID27788A (id) | 2001-04-26 |
KR20010053180A (ko) | 2001-06-25 |
US20060008463A1 (en) | 2006-01-12 |
EP1090924A1 (en) | 2001-04-11 |
KR100653590B1 (ko) | 2006-12-04 |
WO1999067288A9 (fr) | 2000-03-30 |
US7041297B1 (en) | 2006-05-09 |
ES2294844T3 (es) | 2008-04-01 |
EP1090924B1 (en) | 2007-10-10 |
EP1090924A4 (en) | 2002-07-10 |
US7368107B2 (en) | 2008-05-06 |
CN1318447C (zh) | 2007-05-30 |
CN1525980A (zh) | 2004-09-01 |
ATE375362T1 (de) | 2007-10-15 |
JP4413429B2 (ja) | 2010-02-10 |
NZ508996A (en) | 2003-09-26 |
DE69937294T2 (de) | 2008-07-03 |
CA2331761A1 (en) | 1999-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999067288A1 (fr) | Peptides d'antigenes tumoraux provenant de la cyclophiline b | |
JP4904384B2 (ja) | 新規な腫瘍抗原タンパク質sart−3、およびその腫瘍抗原ペプチド | |
US6555652B1 (en) | Tumor antigen peptide derivatives | |
WO2000032770A1 (fr) | Nouvelle proteine d'antigene tumoral art-1 et peptide d'antigene tumoral de cette derniere | |
AU765733B2 (en) | HLA-A2 restraint tumor antigen peptide originating in SART-1 | |
WO2000002907A1 (fr) | Peptide antigene tumoral produit dans le sart-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99809856.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: FORM PCT/RO/134, INDICATIONS RELATING TO A DEPOSITED MICROORGANISM, ADDED (1 PAGE) (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE) |
|
WWE | Wipo information: entry into national phase |
Ref document number: 43926/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 508996 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2331761 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09720469 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007014760 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999926783 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999926783 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007014760 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 43926/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007014760 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999926783 Country of ref document: EP |